Axonics® Announces Fourth Quarter and Full Year 2018 Financial Results and Operational Update

Go back to Axonics® Announces Fourth Quarter and Full Year 2018 Financial Results and Operational Update

Axonics Modulation Technologies Inc. (AXNX) Misses Q4 EPS by 18c, Revenues Beat

March 5, 2019 4:27 PM EST

Axonics Modulation Technologies Inc. (NASDAQ: AXNX) reported Q4 EPS of ($0.50), $0.18 worse than the analyst estimate of ($0.32). Revenue for the quarter came in at $494 thousand versus the consensus estimate of $220 thousand.

In Q4, commercial sales of the miniaturized rechargeable Axonics r-SNM® System totaled $0.5 million.On February 11, filed full-body magnetic resonance imaging (MRI) data with the U.S. Food and Drug Administration (FDA) seeking conditional labeling for the miniaturized rechargeable Axonics r-SNM System.On February 19, disclosed top-line six-month clinical results on the full cohort of patients for the ARTISAN-SNM pivotal clinical study of the... More